Product Description: Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
Applications: COVID-19-immunoregulation
Formula: C22H23N5O2
References: [1]Ludbrook VJ, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95.
CAS Number: 1206163-45-2
Molecular Weight: 389.45
Compound Purity: 99.51
Research Area: Inflammation/Immunology
Solubility: DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target: JAK